Analyst firms · Citizens JMP · NTLA

Citizens JMP NTLA price target and rating history

Intellia Therapeutics Inc. (NTLA) · Health Care

Citizens JMP rates Intellia Therapeutics Inc. (NTLA) Mkt Outperform with a $33 price target, as of its latest action on Oct 6, 2025. It has published 5 rating actions on NTLA since June 2021, including 1 upgrade and 1 downgrade.

Current rating
Mkt Outperform
Price target
$33
Median target, all firms
Too few
Actions on NTLA
5

Citizens JMP price target on NTLA

$175$104$3320222023202420252026
Citizens JMP price target on NTLA, each point a stated target, June 2021 to October 2025.

Every Citizens JMP rating on NTLA

How other firms rate NTLA

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
BarclaysUnderweight$8Oct 6, 2026
Wolfe ResearchUnderperform$9Jul 16, 2026
William BlairOutperformMar 2, 2026

Questions about Citizens JMP and NTLA

What is Citizens JMP's price target for NTLA?
Citizens JMP's latest stated price target for Intellia Therapeutics Inc. (NTLA) is $33, from its action on Oct 6, 2025.
What is Citizens JMP's rating on NTLA?
Citizens JMP rates NTLA Mkt Outperform, a bullish rating, as of Oct 6, 2025.
When did Citizens JMP last change its view on NTLA?
On Oct 6, 2025, Citizens JMP upgrades to Mkt Outperform from Mkt Perform, price target $33.

More NTLA rating histories

All Citizens JMP ratingsNTLA news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.